BiotechTube

Burosumab

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-linked Hypophosphatemia (XLH)

Conditions

X-linked Hypophosphatemia (XLH)

Trial Timeline

Feb 26, 2020 → Mar 6, 2024

NCT ID
NCT04188964

About Burosumab

Burosumab is a phase 1/2 stage product being developed by Kyowa Kirin for X-linked Hypophosphatemia (XLH). The current trial status is completed. This product is registered under clinical trial identifier NCT04188964. Target conditions include X-linked Hypophosphatemia (XLH).

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (10)

NCT IDPhaseStatus
NCT03775187Pre-clinicalActive
NCT05181839Pre-clinicalCompleted
NCT04695860Phase 3Completed
NCT04188964Phase 1/2Completed
NCT03920072Phase 3Completed
NCT02750618Phase 2Completed
NCT02537431Phase 3Completed
NCT02526160Phase 3Completed
NCT02304367Phase 2Completed
NCT02163577Phase 2Completed

Competing Products

20 competing products in X-linked Hypophosphatemia (XLH)

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
28
Methylprednisolone + Prednisolone + SirolimusAstellas PharmaPhase 1/2
41
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1/2
41
KRN23Kyowa KirinPhase 3
77
burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinApproved
85
burosumabKyowa KirinPhase 2
52
BurosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 1/2
41
Placebo + KRN23Kyowa KirinPhase 1
33
BurosumabKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1
33
KRN23Kyowa KirinApproved
85
KK8123Kyowa KirinPhase 1/2
41

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85